Soligenix, Inc. (SNGX)

NASDAQ: SNGX · IEX Real-Time Price · USD
0.730
-0.250 (-25.53%)
At close: Dec 1, 2023, 4:00 PM
0.690
-0.040 (-5.49%)
After-hours: Dec 1, 2023, 7:59 PM EST
-25.53%
Market Cap 7.58M
Revenue (ttm) 960,615
Net Income (ttm) -8.07M
Shares Out 10.38M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,029,085
Open 0.760
Previous Close 0.980
Day's Range 0.711 - 0.890
52-Week Range 0.380 - 10.350
Beta 1.46
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2023

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of infl... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 1987
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SNGX
Full Company Profile

Financial Performance

In 2022, Soligenix's revenue was $948,911, an increase of 15.12% compared to the previous year's $824,268. Losses were -$13.80 million, 9.94% more than in 2021.

Financial Statements

News

"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery

HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J. , Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...

2 days ago - PRNewsWire

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

Pipeline Expansion of Novel Innate Defense Regulator Technology PRINCETON, N.J. , Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutica...

3 days ago - PRNewsWire

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

PRINCETON, N.J. , Nov. 17, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

16 days ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results

PRINCETON, N.J. , Nov. 13, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

20 days ago - PRNewsWire

ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 20, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Small Stocks Big Money® Show, ...

Other symbols: ASPI
6 weeks ago - Accesswire

Soligenix to Present at The ThinkEquity Conference

PRINCETON, N.J. , Oct. 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

6 weeks ago - PRNewsWire

SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 13, 2023 / RedChip Companies will air interviews with SPI Energy Co., Ltd., (NASDAQ:SPI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Small Stocks Big Money® Sho...

Other symbols: SPI
7 weeks ago - Accesswire

Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDA...

Other symbols: GENEKSCP
2 months ago - Accesswire

Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

Vaccines stable for at least two years when stored at 40 degrees Celsius / 104 degrees Fahrenheit Only subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg ...

2 months ago - PRNewsWire

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

PRINCETON, N.J. , Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

2 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

PRINCETON, N.J. ,  August 21, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

3 months ago - PRNewsWire

BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program o...

Other symbols: BIVI
4 months ago - Accesswire

HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Aug. 10, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmac...

4 months ago - PRNewsWire

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Clear biological signal demonstrated; additional patients to be enrolled PRINCETON, N.J. , July 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biophar...

5 months ago - PRNewsWire

Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / June 2, 2023 / RedChip Companies will air new interviews with Soligenix, Inc. (Nasdaq:SNGX) and Graphex Group Limited (NYSE American:GRFX) on The RedChip Money Report® on Bl...

Other symbols: GRFX
6 months ago - Accesswire

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J. , May 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp...

7 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

PRINCETON, N.J. , May 15, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

7 months ago - PRNewsWire

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Update on FDA Meeting Outcome Expected Next Month PRINCETON, N.J. , May 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focus...

7 months ago - PRNewsWire

Soligenix Announces Closing of $8.5 Million Public Offering

PRINCETON, N.J. , May 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

7 months ago - PRNewsWire

Soligenix Announces Pricing of $8.5 Million Public Offering

PRINCETON, N.J. , May 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

7 months ago - PRNewsWire

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 4, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceut...

7 months ago - PRNewsWire

Soligenix Announces Appointment of Timothy R. Coté, M.D.

Strengthens regulatory and orphan drug development expertise PRINCETON, N.J. , May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical com...

7 months ago - PRNewsWire

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J. , May 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Co...

7 months ago - PRNewsWire

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Meeting expected to occur approximately 30 days  from the FDA's receipt of meeting request PRINCETON, N.J. , April 24, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a...

7 months ago - PRNewsWire

Soligenix Provides Regulatory Update on HyBryte™

PRINCETON, N.J. , April 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

8 months ago - PRNewsWire